Advertisement
Advertisement
U.S. markets open in 9 hours 22 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Xencor, Inc. (XNCR)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
36.73+1.05 (+2.94%)
At close: 04:00PM EST
36.73 0.00 (0.00%)
After hours: 04:13PM EST
Advertisement
Sign in to post a message.
  • C
    Crecy
    Jonathan Stempel
    Wed, November 24, 2021, 1:20 PM
    By Jonathan Stempel

    (Reuters) - Pfizer Inc has sued a longtime employee for allegedly stealing "scores" of confidential documents, including some related to its COVID-19 vaccine, as she prepared to jump to a competitor.

    In a complaint filed on Tuesday in San Diego federal court, Pfizer said Chun Xiao Li breached her confidentiality agreement by uploading more than 12,000 files without permission to her personal accounts and devices from her company-issued laptop.

    The alleged materials include a Sept. 24 "playbook" containing internal assessments and recommendations about the Pfizer/BioNTech COVID-19 vaccine, Pfizer's relationship with its German vaccine partner, and presentations related to cancer antibodies.

    Pfizer said Li, an associate director of statistics, tried repeatedly to cover her tracks, even providing a "decoy" laptop to fool it into thinking what she did with the files.

    Li "has misled Pfizer about what she took, how she took it, when and why she did it, and where those files (and possibly others) can be found," the New York-based drugmaker said. ,.....

    Pfizer said Li is resigning after 15 years at the company, and appears to have an offer to join Xencor Inc, a California clinical-stage company focusing on treatments for cancer and autoimmune diseases, on Nov. 29.

    Li could not immediately be reached for comment through her LinkedIn account. Xencor is not a defendant in the lawsuit, and declined to comment.
  • C
    Crecy
    So is this the type of employee Xencor wants ? Chun Xiao Li will be a huge risk to Xencor. She can't be trusted. Hire at your own RISK.
  • L
    Laura
    I am baffled by XNCR's low market cap. It has tons in the pipeline, and it is beginning to earn royalties. Just these two expected income streams warrant a higher market cap:

    1. XNCR's expected royalty payments from MorphoSys in the "high single to low double digits" for tafasitamab. (That was the figure mentioned in the last earning report.) Tafasitamab is expected to be approved in late August (PDUFA) as a second line treatment to the blockbuster $8-ish billion drug Rituxan. I can't imagine Tafasitamab's sales will be under $2b. This is because Tafasitamab is likely to be used either in conjunction with Rituxan or may prove to be better than Rituxan.

    2. XNCR's expected royalty payments from Alexion in the "low single digits" for Ultomiris. Alexion has a market cap of $22.5B and basically, all it has is Ultomiris. So if ALXN is valued at $22.5B, and XNCR is earning only 3% on royalties (3 is just a guess), that alone, would contribute a value of substantially over $0.7 billion. This is due to the fact that royalties are on gross, and ALXN will have expenses related to manufacturing and sales of Ultomiris.
    Bullish
  • B
    Biogemfinder1
    With $GILD licensing $XNCR Technology, you can be sure a big company with way too much cash in the bank and itching to expand its revenue source by acquisition, will be keenly looking at Xencor's pipeline advancement. I Believe
    if any company offered $5B+, BOD will consider that very seriously. But the dilemma for Xencor is that in a year or two, with positive results form Phase I trials of 1-2 programs can catapult its mkt cap 2x3 times easily making it a lot more valuable company. And 10B for buyout!
    Bullish
  • A
    ARedit
    I am looking to start a position here.
  • B
    Biogemfinder1
    $EXEL conversation
    If $EXEL is looking to diversify & add molecules in the clinic quickly w/ premier bi-specific Ab, then it needs to look into collaboration w/ $XNCR .Their collaboration with Genentech $RHHB Janssen $amgn $NVS
    MDAnderson morphosys $MOR Alexion $alxn Astellas (Japan) validates XNCR's technology. It's at least worth a look and there could be hugely beneficial arrangements for both parties. Xencor has very rich pipeline already and I am sure would be happy to have a partner take over some of these advanced molecules as well as with their excellent and much sought after bi-specific technology and premiere engineering platform, have many in early preclinical development. Doesn't mean EXEL needs to jump in but some due diligence and potential partnership would be time well spent. Bi-specific technology of biologics would nicely complement Exelixis' small molecule and ADC pipeline and collaborations.
  • R
    Ryan
    Hearing lots of noise in the industry regarding Xencor. Keep a look out for this one
  • c
    cristian
    XNCR Xencor Inc PDUFA
    When
    Sunday, 30 Aug 2020
    Description
    2020-08-30 The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of August 30, 2020, and Xencor is eligible to receive an additional $25 million regulatory milestone payment related to DLBCL and royalties on net sales in the high-single to low-double digit percentages. http://www.sec.gov/Archives/edgar/data/1326732/000155837020005683/xncr-20200507xex99d1.htm
  • B
    Biogemfinder1
    I fully expect XNCR to beat expectations and then some. There is a good potential for XNCR pps to jump as the partial clinical hold on its promising cd3 bispecific has been lifted. We will see
  • B
    Biogemfinder1
    $EXEL conversation
    @ExelixisInc
    $EXEL needs to approach & strike a deal with $XNCR Xencor Inc. Xencor has interesting pipeline of bispecific Checkpoint Inhibitors such as CTLA4/PD1. Given PD1-Cabo combo is likely to work, Cabo w/ bispecific I/O has immense potential & probably a game changer!
  • B
    Biogemfinder1
    $MOR conversation
    I just doubled my position on Morphosys $MOR It has PDFUA date in August. Approval can happen earlier. Has the potential to cross $50 in short order upon approval. $EXEL $XBI $IBB $GILD $XNCR $PFE $MRK $RHHB $PFE $BMY
  • R
    Ryan
    Too many reasons to buy SAGE to list. Slow market day same mm's parked, crowded, and stacking SAGE for the launch back where it was. When market volume and a strong green day come back or press release on depression 217 which was different than what todays release was about, look out 200's.
  • K
    Kev
    Genentech, a member of the Roche group, will partner with Xencor to develop and commercialize its novel IL-15 cytokine therapeutics—including its most advanced preclinical cytokine program, the cancer candidate XmAb®24306, through a collaboration tha
    Genentech, a member of the Roche group, will partner with Xencor to develop and commercialize its novel IL-15 cytokine therapeutics—including its most advanced preclinical cytokine program, the cancer candidate XmAb®24306, through a collaboration tha
    www.genengnews.com
  • B
    Biogemfinder1
    Based on what GILD is paying KITE, XNCR should be worth $5B now and approval of ANY CD3 bi-specific, easily $10B market cap. This is the bottom line, with all the hoopla and hype regarding CAR-T what the Gilead management and wall street may be overlooking is the COGS (cost of goods), which is tremendous due to personalized nature of manufacturing and hospital use to administer the "drug". In addition, to anyone who knows how CD3 bi-specifics work vs CAR-T technology, they work almost identically (harnessing the tumor-killing property of individual's own T cells). However, CD3 bi-specifics do it in a more elegant and "manufacturerable" way at a fraction of the cost. If you know this fact, you will be betting on "CD3 bi-specifics" leaders of which Xencor is definitely one. GILD overpaid it and Kite smartly took the deal. There is some much competition in NHL and more coming up, and yes the proof of concept of either CAR-T or CD3 is still lacking as far as "solid" tumors are concerned. Time will tell..but I am starting to accumulate XNCR as they have many shots on goal including auto-immune and allergy indications on top of the robust oncology pipeline. 2-3 years from now we are talking about $5B or more in market cap!!
  • c
    cristian
    FDA Calendar – FDA Tracker
    www.fdatracker.com
  • Y
    Yahoo Finance Insights
    XNCR is up 5.79% to 39.99
  • Y
    Yahoo Finance Insights
    XNCR is up 5.64% to 41.77
  • Y
    Yahoo Finance Insights
    XNCR is up 6.32% to 42.67
  • m
    mike
    I can not understand why Xencor is trading so low. Royalties from Ultomiris are beginning. 25 million for Q1 2019 is not much, but this will pick up quick.

    Perhaps the market waits for the filing of MOR208 which will be big money for Xencor.
  • Y
    Yahoo Finance Insights
    XNCR is down -5.22% to 35.22
Advertisement
Advertisement